S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:PSNL - Personalis Stock Price, Forecast & News

$9.62
-0.24 (-2.43 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$9.57
Now: $9.62
$10.14
50-Day Range
$8.73
MA: $9.94
$11.96
52-Week Range
$8.48
Now: $9.62
$31.88
Volume258,812 shs
Average Volume349,593 shs
Market Capitalization$300.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSNL
CUSIPN/A
CIKN/A
Phone650-752-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees147
Market Cap$300.47 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.


Personalis (NASDAQ:PSNL) Frequently Asked Questions

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How were Personalis' earnings last quarter?

Personalis (NASDAQ:PSNL) posted its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $17.20 million for the quarter, compared to analysts' expectations of $15.77 million. The business's quarterly revenue was up 47.0% on a year-over-year basis. View Personalis' Earnings History.

When is Personalis' next earnings date?

Personalis is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Personalis.

What guidance has Personalis issued on next quarter's earnings?

Personalis issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$64.5-65 million, compared to the consensus revenue estimate of $$61.68 million.

What price target have analysts set for PSNL?

5 brokerages have issued 12 month target prices for Personalis' stock. Their forecasts range from $22.00 to $29.00. On average, they anticipate Personalis' share price to reach $26.25 in the next year. This suggests a possible upside of 172.9% from the stock's current price. View Analyst Price Targets for Personalis.

What is the consensus analysts' recommendation for Personalis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Personalis.

Has Personalis been receiving favorable news coverage?

Press coverage about PSNL stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Personalis earned a daily sentiment score of -1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Personalis.

Are investors shorting Personalis?

Personalis saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 886,700 shares, an increase of 14.8% from the November 14th total of 772,400 shares. Based on an average daily trading volume, of 295,900 shares, the short-interest ratio is presently 3.0 days. Approximately 5.5% of the shares of the company are sold short. View Personalis' Current Options Chain.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Honeywell International (HON), Raytheon (RTN), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), NVIDIA (NVDA), Verizon Communications (VZ) and Amgen (AMGN).

Who are Personalis' key executives?

Personalis' management team includes the folowing people:
  • Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)
  • Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board

When did Personalis IPO?

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager.

When does Personalis' lock-up period expire?

Personalis' lock-up period expires on Tuesday, December 17th. Personalis had issued 7,921,500 shares in its IPO on June 20th. The total size of the offering was $134,665,500 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are Personalis' major shareholders?

Personalis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (2.58%), Sumitomo Mitsui Trust Holdings Inc. (2.58%), Orbimed Advisors LLC (1.55%), Emerald Advisers LLC (1.05%), Kornitzer Capital Management Inc. KS (0.90%) and Emerald Mutual Fund Advisers Trust (0.82%). View Institutional Ownership Trends for Personalis.

Which major investors are buying Personalis stock?

PSNL stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Emerald Advisers LLC, Orbimed Advisors LLC, Emerald Mutual Fund Advisers Trust, State Street Corp, Gabelli Funds LLC and Wellington Shields Capital Management LLC. View Insider Buying and Selling for Personalis.

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $9.62.

How big of a company is Personalis?

Personalis has a market capitalization of $300.47 million. Personalis employs 147 workers across the globe.View Additional Information About Personalis.

What is Personalis' official website?

The official website for Personalis is http://www.personalis.com/.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]


MarketBeat Community Rating for Personalis (NASDAQ PSNL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote "Outperform" if you believe PSNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel